Drawing for MOLECULAR HEALTH MH GUIDE

USPTO serial 87048025

MOLECULAR HEALTH MH GUIDE

Reviewed by CopyMark Law Group

Reg. 5566271Status 702Registered
Filing date
Status date
Registration date
Sep 18, 2018
Examiner
HISER, CHARLES
Law office
Historical data usage

What this means

Status 702 means the registration is active, Section 8 was accepted, and a Section 15 declaration of incontestability was also accepted. Incontestability strengthens your rights by limiting certain challenges after five years of continuous use. Continue use in commerce and plan for the 10-year Section 8 and 9 renewal.

Status 702: Status 702 means the registration is active, Section 8 was accepted, and a Section 15 declaration of incontestability was also accepted. Incontestability strengthens your rights by limiting certain challenges after five years of continuous use.

Need help with MOLECULAR HEALTH MH GUIDE?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Peter T. Wakiyama

Peter T. Wakiyama Troutman Pepper Hamilton Sanders LLP3000 Two Logan Square, Eighteenth And ArEighteenth and Arch StreetsPHILADELPHIA, PA 19103

Goods and services

ClassDescriptionStatusFirst use
009Downloadable computer databases containing information in the fields of medicine, health care, genomics, bioinformatics, pharmaceuticals, life sciences and biotechnology; downloadable computer databases containing medical and health information on humans; downloadable computer software for accessing, organizing, indexing, ranking, integrating, linking, referencing, synthesizing, interpreting and analyzing information from databases in the fields of medicine, health care, genomics, pharmaceuticals, life sciences and biotechnology and databases containing medical and health information or records about or relating to humans; downloadable mobile applications for mobile devices, for accessing, organizing, synthesizing, indexing, ranking, integrating, linking, referencing, interpreting and analyzing information from databases in the fields of medicine, health care, genomics, bioinformatics, pharmaceuticals, life sciences and biotechnology and databases containing medical and health information or records about or relating to humans; downloadable mobile applications for accessing databases in the fields of medicine, health care, genomics, bioinformatics, pharmaceuticals and pharmaceutical safety, life sciences and biotechnologyACTIVEJun 3, 2016
038Providing access to searchable databases containing medical, pharmaceutical, biological, clinical and genomic information and medical and health information and records, molecular test results and patient specific data about or relating to humans for scientific research purposes; providing access to online databases containing medical, pharmaceutical, biological, clinical, molecular, sequencing and genomic information, disease information, biomarker information and medical or health information or records about or relating to humans and patient specific data, molecular test results, and scientific research for medical diagnostic and treatment purposes; providing access to online software and algorithms for retrieval, integration, correlation, analysis and interpretation of genomic, sequencing and molecular data, diseases, biomarkers, drug protocols, drug interactions, clinical profiles, and medical and health information, records or data, and patient specific data, molecular test results, data from clinical studies, and scientific research for medical diagnostic and treatment purposes; providing access to non-downloadable computer software and algorithms for medical diagnostic and treatment purposesACTIVEJun 3, 2016
042Consulting and research services in the fields of health care, medicine, life sciences, biotechnology, pharmaceuticals, bioinformatics, life sciences, genomics and pharmaceuticals and pharmaceutical safety for scientific research purposes; consulting and research services in the nature of retrieval, integration, correlation, analysis and interpretation of genomic, sequencing, and molecular data and information on diseases, biomarkers, drug protocols, drug interactions, clinical profiles, medical health information patient specific data, molecular test results, data from clinical studies, and scientific research for purposes of scientific, medical and pharmaceutical research; designing and developing searchable databases containing medical, pharmaceutical, biological, clinical and genomic information and medical and health information and records, molecular test results and patient specific data about or relating to humans for scientific research purposes; providing temporary use to non-downloadable computer software and algorithms for retrieval, integration, correlation, analysis and interpretation of genomic, sequencing and molecular data and information on diseases, biomarkers, drug protocols, drug interactions, clinical profiles, and medical and health information, patient specific data, molecular test results, data from clinical studies, and scientific research for use by physicians, clinicians and other healthcare professionals, laboratory personnel, consultants, scientists and other researchers for purposes of scientific, medical and pharmaceutical research; providing temporary use to non-downloadable computer software and algorithms for retrieval, integration, correlation, analysis and interpretation of genomic, sequencing and molecular data and information on diseases, biomarkers, drug protocols, drug interactions, clinical profiles, and medical and health information, patient specific data, molecular test results, data from clinical studies, and scientific research for purposes of scientific, medical and pharmaceutical research; providing temporary use to non-downloadable applications for mobile devices, namely, smart phones and tablets, and web applications accessible through the internet providing information in the fields of medicine, health care, genomics, bioinformatics, pharmaceuticals, life sciences and biotechnology for scientific research purposes; data collection services for scientific research purposes in the fields of genomics, health care, pharmaceuticals, life sciences, bioinformatics, biotechnology and medicine; services for mobile devices, namely, smart phones and tablets, being software design; non-downloadable web applications for accessing databases accessible through the internet in the fields of medicine, health care, genomics, bioinformatics, pharmaceuticals and pharmaceutical safety, life sciences and biotechnology; providing temporary use of non-downloadable computer software and algorithms for retrieval, integration, correlation, analysis and interpretation of genomic, sequencing and molecular data and information on diseases, biomarkers, drug protocols, drug interactions, clinical profiles, and medical and health information, patient specific data, molecular test results, data from clinical studies, and scientific research for medical diagnostic and treatment purposes; medical research services, namely, the retrieval, integration, correlation, analysis and interpretation of genomic, sequencing and molecular data, diseases, biomarkers, drug protocols, drug interactions, clinical profiles, and medical and health information, records or data, and patient specific data, molecular test results, data from clinical studies, and scientific research for medical diagnostic and treatment purposesACTIVEJun 3, 2016
044Medical consulting services, namely, the retrieval, integration, correlation, analysis and interpretation of genomic, sequencing and molecular data, diseases, biomarkers, drug protocols, drug interactions, clinical profiles, and medical and health information, records or data, and patient specific data, molecular test results, data from clinical studies, and scientific research for medical diagnostic and treatment purposes; consulting services in the fields of medical care, pharmaceuticals and medicine; providing medical information in the fields of health, healthcare, life sciences, biotechnology, pharmaceuticals and pharmaceutical safety, bioinformatics, and genetic testing for medical purposes; medical consulting services with respect to the treatment and diagnosis of individuals; providing medical information on drug safety and drug compatibility in relation to therapy and the treatment of individuals; medical consulting services in the fields of diagnostics and patient treatment and treatment protocolsACTIVEJun 3, 2016

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Jan 31, 2025NA85NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED—
Jan 31, 2025C15AREGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.—
Jan 31, 2025APRECASE ASSIGNED TO POST REGISTRATION PARALEGAL—
Sep 13, 2024E815TEAS SECTION 8 & 15 RECEIVED—
Sep 18, 2023REM1COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED—
Sep 18, 2018R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Aug 17, 2018SUNANOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED—
Aug 16, 2018CNPRALLOWED PRINCIPAL REGISTER - SOU ACCEPTED—
Jul 24, 2018SUPCSTATEMENT OF USE PROCESSING COMPLETE—
Jul 11, 2018IUAFUSE AMENDMENT FILED—
Jul 11, 2018EISUTEAS STATEMENT OF USE RECEIVEDThe applicant filed a Statement of Use with specimens showing the mark in actual commerce. The USPTO will review the filing for compliance. If accepted, the mark can proceed to registration; if deficient, the USPTO may issue a requirement or office action.
Jul 11, 2018TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Feb 21, 2018EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Feb 20, 2018EX1GSOU EXTENSION 1 GRANTED—
Feb 20, 2018AITUCASE ASSIGNED TO INTENT TO USE PARALEGAL—
Feb 5, 2018NREVNOTICE OF REVIVAL - E-MAILED—
Feb 5, 2018TPEXSOU EXTENSION RECEIVED WITH TEAS PETITION—
Feb 5, 2018PETGPETITION TO REVIVE-GRANTED—
Feb 5, 2018PROATEAS PETITION TO REVIVE RECEIVED—
Jan 11, 2018EXT1SOU EXTENSION 1 FILED—
Jul 11, 2017NOAMNOA E-MAILED - SOU REQUIRED FROM APPLICANTA Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
May 16, 2017NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
May 16, 2017PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Apr 26, 2017NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Apr 6, 2017CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Apr 5, 2017TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Apr 5, 2017CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Apr 5, 2017TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Mar 27, 2017GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Mar 27, 2017GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Mar 27, 2017CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Mar 16, 2017TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Mar 15, 2017CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Mar 15, 2017TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Sep 15, 2016GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Sep 15, 2016GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Sep 15, 2016CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Sep 8, 2016DOCKASSIGNED TO EXAMINER—
Jun 2, 2016MDSCNOTICE OF DESIGN SEARCH CODE E-MAILED—
Jun 1, 2016NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
May 27, 2016NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance